Resmetirom: Breakthrough therapeutic approach for metabolic dysfunction-associated steatohepatitis  

作　　者：Anzel Saeed Kuldeep Dalpat Rai 

机构地区：[1]Department of Medicine,Dow Medical College,Dow University of Health Sciences,Karachi,Pakistan

出　　处：《Liver Research》2024年第3期193-194,共2页肝脏研究（英文）

摘　　要：To the editor,Metabolic dysfunction-associated steatohepatitis(MASH)is the active and progressive stage of metabolic dysfunction-associated steatotic liver disease,characterized by the presence of lipid accumulation in hepatocytes with inflammation and hepatocyte injury(e.g.,ballooning),with or without fibrosis.1 Patients with advanced MASH fibrosis experience increased morbidity and mortality due to progression of liver disease,including progression to cirrhosis,liver failure,and hepatocellular carcinoma.2,3 Currently,there is no approved therapy for MASH,and its prevalence has increased with the increasing global prevalence of obesity.4,5 Similar to other metabolic diseases,lifestyle modifications are effective for managing MASH but are difficult to implement and maintain.

关 键 词：BALLOON prevalence MORTALITY 

分 类 号：R575.1[医药卫生—消化系统]